Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 22, 2026
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
10:02am, Tuesday, 07'th Oct 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests today announced the publication of “Comparing Benefit-to-Burden Ratio
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock
10:46am, Thursday, 02'nd Oct 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exact Sciences (EXAS) Just Flashed Golden Cross Signal: Do You Buy?
10:36am, Wednesday, 01'st Oct 2025
Exact Sciences (EXAS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EXAS crossed above the 20-day moving average, suggestin
Exact Sciences' Clear Expansion Path: Why Choose To Buy
05:07am, Thursday, 25'th Sep 2025
Exact Sciences earns a BUY rating, driven by innovation in non-invasive cancer detection and the recent launch of Cancerguard. EXAS's core products—Cologuard, Oncotype DX, and OncoDetect—deliver s
Why Exact Sciences (EXAS) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 22'nd Sep 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with actor and horror icon Matthew Lillard to encourage
Healthmine and Exact Sciences Partner to Combine At-Home CRC Screening with Health Plan Incentives to Boost Preventive Care
08:30am, Wednesday, 17'th Sep 2025
DALLAS--(BUSINESS WIRE)--Healthmine and Exact Sciences partner to increase colorectal cancer screening rates through at-home testing and health plan incentives.
Exact Sciences CEO on Launch of Multi-Cancer Blood Test
03:30pm, Monday, 15'th Sep 2025
Exact Sciences CEO and Chair Kevin Conroy discusses the company's new multi-cancer blood test and competitive environment. Speaking on "Bloomberg Open Interest," Conroy also comments on President Dona
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term
10:46am, Monday, 15'th Sep 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
09:55am, Friday, 12'th Sep 2025
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
Should You Continue to Hold EXAS Stock in Your Portfolio?
11:05am, Wednesday, 10'th Sep 2025
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.
Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test
06:30am, Wednesday, 10'th Sep 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) bl
Exact Sciences Corporation (EXAS) Presents At Baird 2025 Global Healthcare Conference (Transcript)
04:49pm, Tuesday, 09'th Sep 2025
Exact Sciences Corporation (NASDAQ:EXAS ) Baird 2025 Global Healthcare Conference September 9, 2025 10:50 AM EDT Company Participants Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief F
Exact Sciences Corporation (EXAS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
04:14pm, Wednesday, 03'rd Sep 2025
Exact Sciences Corporation (NASDAQ:EXAS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Aaron Bloomer - Chief Financial Officer Conference Call
